It looks like this podcast has ended some time ago. This means that no new episodes have been added some time ago. If you're the host of this podcast, you can check whether your RSS file is reachable for podcast clients.
GRACEcast ALL Subjects audio and video
by cancerGRACE - H. Jack West, MDOncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Copyright: Copyright 2013 GRACE - All Rights Reserved
Episodes
Does Gilotrif Help EGFR Positive Lung Cancer Patients?
8m · PublishedAn analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
The Promise of Immunotherapy in Lung Cancer
1m · PublishedDr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.
Is Progression-Free Survival Meaningful?
3m · PublishedProgression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?
DDR2 Mutations in Squamous Cell Lung Cancer
1m · PublishedA genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.
Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?
9m · PublishedDrs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.
What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?
3m · PublishedDr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.
How Do We Make EGFR Inhibitors Work Better for Patients
3m · PublishedDr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
TH 302: New Drug May Make Tumors Less Resistant to Treatment
1m · PublishedDr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
Should We Do Broad Sequencing of All Lung Tumors?
3m · PublishedHow much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.
How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
4m · PublishedXalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
GRACEcast ALL Subjects audio and video has 300 episodes in total of non- explicit content. Total playtime is 27:43:00. The language of the podcast is English. This podcast has been added on November 27th 2022. It might contain more episodes than the ones shown here. It was last updated on May 31st, 2023 02:05.
